Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 631

1.
2.
3.

Comparative study of the efficacy of an induction dose of interferon-alpha2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C.

Pérez R, Jiménez M, Crespo J, Diago M, Enríquez J, Vaquero P, Solá R, Olcoz JL, Romero M, Salmerón J, Blanco MI, Oña M, Melón S, Rodrigo L; Grupo Inter-Hospitalario Español.

J Viral Hepat. 2003 Nov;10(6):437-45.

PMID:
14633177
4.

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.

Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O.

Lancet. 1998 Jan 10;351(9096):83-7.

PMID:
9439491
5.

Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial.

Berg T, Hoffmann RM, Teuber G, Leifeld L, Lafrenz M, Baumgarten R, Spengler U, Zeuzem S, Pape GR, Hopf U.

Liver. 2000 Dec;20(6):427-36.

PMID:
11169056
6.

Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.

Di Marco V, Almasio P, Vaccaro A, Ferraro D, Parisi P, Cataldo MG, Di Stefano R, Craxì A.

J Hepatol. 2000 Sep;33(3):456-62.

PMID:
11020002
7.
8.

Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study.

Portal I, Bourlière M, Halfon P, De Lédinghen V, Couzigou P, Bernard PH, Blanc F, Caroli-Bosc F, Arpurt JP, Vetter D, Mathieu-Chandelier C, Chazouillères O, Thiefin G, Pol S, Sogni P, Abergel A, Bailly F, Picon M, Debonne JM, Zamora C, Alleman I, Moreau X, Doll F, Eugène C, Ducloux S, Larrey D, Ouzan D, Grimaud JC, Gouvernet J, Botti G, Gérolami V, Khiri H, Gérolami A, Gauthier AP, Botta-Fridlund D.

J Viral Hepat. 2003 May;10(3):215-23.

PMID:
12753341
9.

Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.

Enríquez J, Gallego A, Torras X, Pérez-Olmeda T, Diago M, Soriano V, Luján MS, García-Samaniego J.

J Viral Hepat. 2000 Nov;7(6):403-8.

PMID:
11115050
10.

Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.

El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, El-Nakeeb A, Selim O, Saied A.

Am J Gastroenterol. 2005 Nov;100(11):2447-52.

PMID:
16279899
11.

Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C.

Cheng PN, Chow NH, Hu SC, Young KC, Chen CY, Jen CM, Chang TT.

Dig Liver Dis. 2002 Dec;34(12):851-6.

PMID:
12643293
12.

The effect of pegylated interferon-alpha2b and ribavirin combination therapy for chronic hepatitis C infection in elderly patients.

Nishikawa H, Iguchi E, Koshikawa Y, Ako S, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Ishikawa T, Saito S, Kita R, Kimura T, Osaki Y.

BMC Res Notes. 2012 Mar 10;5:135. doi: 10.1186/1756-0500-5-135.

13.

First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C.

Reiser M, Buggisch P, Grossmann J, Koop K, Wursthorn K, Schmiegel W.

Eur J Gastroenterol Hepatol. 2003 Dec;15(12):1299-304.

PMID:
14624153
14.

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK.

Lancet. 2001 Sep 22;358(9286):958-65.

PMID:
11583749
15.

Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.

Roffi L, Colloredo G, Pioltelli P, Bellati G, Pozzpi M, Parravicini P, Bellia V, Del Poggio P, Fornaciari G, Ceriani R, Ramella G, Corradi C, Rossini A, Bruno S; Gruppo Epatologico Lombardo.

Antivir Ther. 2008;13(5):663-73.

PMID:
18771050
16.
17.

Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.

Poynard T, Marcellin P, Bissery A, Myers RP, Moussalli J, Degos F, Dhumeaux D, Riachi G, Bronowicki JP, Brissot P, Buffet C, Serfaty L, Naveau S, Sogni P, Beaugrand M, Gayno S, Larrey D, Samuel D, Eugene C, Pol S, Bedossa P, Daurat V, Chaumet-Riffaud P; GER-CYT-RIBANON group.

J Viral Hepat. 2003 May;10(3):197-204.

PMID:
12753338
19.

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.

Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.

J Gastroenterol Hepatol. 2008 Jun;23(6):861-6. doi: 10.1111/j.1440-1746.2008.05397.x. Epub 2008 Apr 19.

PMID:
18422960
20.

Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.

Sjogren MH, Sjogren R, Holtzmuller K, Winston B, Butterfield B, Drake S, Watts A, Howard R, Smith M.

Dig Dis Sci. 2005 Apr;50(4):727-32.

PMID:
15844709

Supplemental Content

Support Center